Three-Year Survival Outcomes to First-Line Pembrolizumab Monotherapy in NSCLC With PD-L1 TPS 50% to 89% Versus Greater Than or Equal to 90%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.